Merit Medical Systems has acquired US-based Biolife Delaware, a manufacturer of haemostatic devices, in a $120m deal.
The transaction value was paid in cash alongside the assumption of Biolife’s liabilities.
Go deeper with GlobalData
The acquisition enhances Merit’s offerings, providing clinicians with products aimed at streamlining post-procedure care.
Biolife’s haemostatic devices are manufactured under the StatSeal and WoundSeal brand names.
Merit’s products will benefit from the addition of StatSeal, which claims to quickly form a protective seal over the procedure area.
The integration of StatSeal is expected to complement a variety of percutaneous procedures, spanning several medical specialities.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataMerit anticipates that the assets acquired, which generated around $15m in revenue over the year ending 31 December 2024, will contribute between $10m and $11m in revenue from the effective merger date of 20 May 2025 to the end of the year.
However, the acquisition is expected to dilute Merit’s non-generally accepted accounting principles (GAAP) net income and earnings per share, considering the purchase costs and excluding certain transaction-related expenses.
Biolife’s product line includes a powder containing potassium ferrate and a hydrophilic polymer as the ingredients.
The products work independently of clotting mechanisms for sealing the wounds and the vascular access region.
Piper Sandler & Co provided financial advisory services to Merit for the acquisition.
Parr Brown Gee & Loveless and Nelson Mullins Riley & Scarborough served as legal advisers to Merit and Biolife, respectively.
Merit Medical Systems CEO and chairman Fred Lampropoulos said: “The acquisition provides effective, differentiated, haemostatic solutions for all percutaneous devices with a broad range of clinical applications, including vascular closure and indwelling catheter bleeding complications.
“BioLife’s StatSeal and WoundSeal products address an estimated $350m global market opportunity, are clinically validated, and will enhance our ability to deliver comprehensive solutions to our customers.”
Before this development, Health Canada approved Merit Medical’s Wrapsody cell-impermeable endoprosthesis device to help physicians in prolonging functional vascular access in haemodialysis patients.
